Phase I Clinical Study of HRS-9815 for PET/CT Imaging in Patients With Prostate Cancer

• Status: Not yet recruiting
• Trial end date: 2023-12-01
• Target enrollment: 0
• Participant gender: Male

Summary

The study is being conducted to evaluate the the safety, pharmacokinetics, radiation dosimetry of HRS-9815 for PET/CT imaging in adult patients with prostate cancer.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Criteria

Inclusion Criteria:

1. Voluntary participation in this clinical trial, understanding of the study procedures and being able to sign the informed consent form in writing;

2. Male, age ≥18 years;

3. ECOG score 0 - 1;

4. Histologically confirmed adenocarcinoma of the prostate;

Exclusion Criteria:

1. Severe urinary incontinence, hydronephrosis, severe micturition dysfunction, etc. Note: Subjects with bladder outflow obstruction or urinary incontinence that can be controlled by the best available standard of care (including pads, drainage, etc.) are eligible to participate in the study.

2. Active syphilis infection.

3. Known allergy, hypersensitivity, or contraindication to the trial product or any component of its formulation.。

4. Active in other clinical studies or less than 4 weeks after the last dose in the previous clinical study at the time of the first dose.